The primary objective of the study is to evaluate changes in weight short and long term with bifeprunox and quetiapine. Study participation for the subject is 57 weeks.
52 weeks of fixed oral doses of bifeprunox at 30 mg/day administered as a single dose with 1 week upward titration from 0.25 mg/day dose. Placebo will be used for evening dose.
Fixed oral dose of quetiapine at 400 mg/day to be administered in divided doses (BID) utilizing a 5-day upward titration from 50 mg/day.
52 weeks of fixed oral doses of bifeprunox at 30 mg/day administered as a single dose with 2 week upward titration from 0.25 mg/day dose. Placebo will be used for evening dose.
Buenos Aires, Argentina
Buenos Aires, Argentina
Córdoba, Argentina
Córdoba, Argentina
La Plata, Argentina
Little Rock, Argentina
Mendoza, Argentina
Mendoza, Argentina
Mendoza, Argentina
Rosario, Argentina